Praneeth Baratam

[NEJM @NEJM]

In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. Full PARADIGM trial results: https://t.co/iiDNsw6CUW

Editorial: Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML https://t.co/zsAPQjxEDb

[Georgio Medawar, MD @GeorgioMedawar]

A landmark pre-clinical study in @Nature shows in vivo mRNA delivery to HSPCs through a lipid nanoparticule conjugated to anti-CD34 can lead to efficient editing w/ gene function restoration w/o perturbing hematopoiesis - a leap into the future!

https://t.co/jNHOsFUQbx

[AML Hub @AML_Hub]

CONGRESS | #EHA2026 | POSTER
Cecilia Arana Yi presents real-world outcomes of patients with MECOMr AML from the COMMAND MARROW consortium, and Flatiron database.
In this population, survival was poor and half of responders relapsed. Intensive chemotherapy resulted in higher remission rates vs HMAs or HMA+Venetoclax. These findings confirm the need for improved treatment strategies for this AML subtype.

Follow our live feed for more updates: https://t.co/ekn3HdrQLM

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#AMLsm #leusm #MedicalCongress #MedNews #MedEd @Dr_Cecilia_Yi @MayoClinic

[Talha Badar @TalhaBadarMD]

#EHA2026 #AML #leusm

Dr. Barote: OPTI-AML: the first prospective RCT of Ven 14d vs 28d + Aza ×2 cycles in older AML — and it reframes the whole “shorter is fine” debate.

AV14 did NOT meet non-inferiority for CR (43% vs 49% AV28; ΔCI –8% to +21%, upper bound >10%).

Key takeaways 👇🏽

But the real story is molecular, not calendar:
• NPM1 & IDH1/2 → favored 28d (61% vs 42%)
• Every other subset → 44% vs 44%, identical

And cumulative delivery, not the planned schedule, tracked with response: pts who couldn’t complete Ven had lower CR in BOTH arms (AV28 39% vs 56%; AV14 36% vs 49%). Only 68% of AV28 finished C1 Ven (vs 89%) — mostly infections.

MRD negativity (78% vs 77%) and toxicity were superimposable. OS numerically favored AV28 but on MVA was driven by TP53/KRAS + counts, not arm.

Bottom line: Ven duration should be titrated to molecular subtype + triplet partner — what matters is cumulative exposure delivered, and for NPM1/IDH that exposure still earns its keep. #EHA2026 #EHA26

[Praneeth Baratam @BaratamPraneeth]

Incredible moment in the history of AML therapeutics. The prospect of all oral, all outpatient AML treatment is a reality now and all future therapeutics will be judged against this standard.

[CancerNetwork® @CancerNetwrk]

🚨 The FDA approved oral decitabine and cedazuridine tablets with venetoclax for newly diagnosed AML in adults ≥75 years, or who have comorbidities that preclude the use of intensive induction chemotherapy.

https://t.co/z8MRDvataW

#leusm #AML #leukemia #oncology | @FDAOncology

[CancerNetwork® @CancerNetwrk]

🚨 The FDA approved oral decitabine and cedazuridine tablets with venetoclax for newly diagnosed AML in adults ≥75 years, or who have comorbidities that preclude the use of intensive induction chemotherapy.

https://t.co/z8MRDvataW

#leusm #AML #leukemia #oncology | @FDAOncology

[Praneeth Baratam @BaratamPraneeth]

#ASH2025 Another great kickoff picture with our excellent fellows and faculty #musc

[Blood Advances @BloodAdvances]

Patients with TP53-mutated AML/MDS represent a unique and heterogeneous high-risk group that should not be treated as 1 single entity. https://t.co/XfVyEbfJlJ #myeloidneoplasia #transplantation #clinicaltrialsandobservations

[Hagop Kantarjian,MD @DrHKantarjian]

In this large retrospective study of FLT3-mutated AML, we confirm the important role of FLT3 inhibitors in intensively treated pts and demonstrate promising outcomes w/ low-intensity triplets in older/unfit pts.
@MDAndersonNews #Leukemia
@JournalCancer
https://t.co/OZy6PCMCjD

[Praneeth Baratam @BaratamPraneeth]

Neutrophil recovery is quick, happening in 15 days, and sustained in IDH1 mutant R/R MDS. Happy to have reported on this data at #ASH2024. Thanks to all my co investigators and patients who took part in this study.
https://t.co/Y6JoNai4sO

[Praneeth Baratam @BaratamPraneeth]

A game changer for ethnic minorities... Thanks Amy, Rob and team.

[Robert Brodsky @DocsDock200]

Important advance for patients with severe aplastic anemia in latest issue of Blood: Upfront haploidentical BMT. @pnhaacontact @aamdsif #aplastic

[Praneeth Baratam @BaratamPraneeth]

Good luck y'all!!! Your class was fun!

[Praneeth Baratam @BaratamPraneeth]

Drexel/Hahnemann lives on and represented at #ASH2022